230 related articles for article (PubMed ID: 22947349)
1. Asymptomatic thyrotropin-secreting pituitary macroadenoma in a 13-year-old girl: successful first-line treatment with somatostatin analogs.
Rabbiosi S; Peroni E; Tronconi GM; Chiumello G; Losa M; Weber G
Thyroid; 2012 Oct; 22(10):1076-9. PubMed ID: 22947349
[TBL] [Abstract][Full Text] [Related]
2. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
Kuhn JM; Arlot S; Lefebvre H; Caron P; Cortet-Rudelli C; Archambaud F; Chanson P; Tabarin A; Goth MI; Blumberg J; Catus F; Ispas S; Beck-Peccoz P
J Clin Endocrinol Metab; 2000 Apr; 85(4):1487-91. PubMed ID: 10770186
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas.
Caron P; Arlot S; Bauters C; Chanson P; Kuhn JM; Pugeat M; Marechaud R; Teutsch C; Vidal E; Sassano P
J Clin Endocrinol Metab; 2001 Jun; 86(6):2849-53. PubMed ID: 11397898
[TBL] [Abstract][Full Text] [Related]
5. Long-term preoperative management of thyrotropin-secreting pituitary adenoma with octreotide.
Iglesias P; Díez JJ
J Endocrinol Invest; 1998 Dec; 21(11):775-8. PubMed ID: 9972679
[TBL] [Abstract][Full Text] [Related]
6. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide).
Caron P; Gerbeau C; Pradayrol L; Simonetta C; Bayard F
J Clin Endocrinol Metab; 1996 Mar; 81(3):1164-8. PubMed ID: 8772594
[TBL] [Abstract][Full Text] [Related]
7. A thyrotropin-secreting macroadenoma with positive growth hormone and prolactin immunostaining: A case report and literature review.
Kuzu F; Bayraktaroğlu T; Zor F; G N BD; Salihoğlu YS; Kalaycı M
Niger J Clin Pract; 2015; 18(5):693-7. PubMed ID: 26096253
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
9. Effect of octreotide acetate on thyrotropin-secreting adenoma: report of two cases and review of the literature.
Yoenem A; Cakyr B; Azal O; Corakcy A; Kutlu M; Oezata M
Endocr Regul; 1999 Dec; 33(4):169-74. PubMed ID: 10700085
[TBL] [Abstract][Full Text] [Related]
10. TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide.
Fischler MP; Reinhart WH
J Endocrinol Invest; 1999 Jan; 22(1):64-5. PubMed ID: 10090139
[TBL] [Abstract][Full Text] [Related]
11. Long term treatment of a thyrotropin-secreting microadenoma with somatostatin analogues.
Prieto-Tenreiro A; Díaz-Guardiola P
Arq Bras Endocrinol Metabol; 2010; 54(5):502-6. PubMed ID: 20694413
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
13. [Somatostatin analogs in the clinical management of pituitary neoplasms].
Colao A; Dorato M; Pulcrano M; Rossi FW; Auriemma RS; Lombardi G; Lastoria S
Minerva Endocrinol; 2001 Sep; 26(3):181-91. PubMed ID: 11753242
[TBL] [Abstract][Full Text] [Related]
14. [Thyrotropin--TSH secreting pituitary tumor].
Zieliński G; Podgórski JK; Warczyńska A; Koziarski A; Zgliczyński W
Przegl Lek; 2002; 59(12):1018-23. PubMed ID: 12731380
[TBL] [Abstract][Full Text] [Related]
15. Preoperative long-acting octreotide treatment for invasive thyrotropin-secreting pituitary macroadenoma after previous radioiodine thyroid ablation.
Gruszka A; Zielinski GM; Kunert-Radek J
J Clin Neurosci; 2014 Feb; 21(2):340-2. PubMed ID: 23958483
[TBL] [Abstract][Full Text] [Related]
16. Reduction in size of a thyrotropin- and gonadotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog).
Sy RA; Bernstein R; Chynn KY; Kourides IA
J Clin Endocrinol Metab; 1992 Mar; 74(3):690-4. PubMed ID: 1740506
[TBL] [Abstract][Full Text] [Related]
17. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P
J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
[TBL] [Abstract][Full Text] [Related]
18. Management of coexisting thyrotropin/growth-hormone-secreting pituitary adenoma and papillary thyroid carcinoma: a therapeutic challenge.
Nguyen HD; Galitz MS; Mai VQ; Clyde PW; Glister BC; Shakir MK
Thyroid; 2010 Jan; 20(1):99-103. PubMed ID: 20067380
[TBL] [Abstract][Full Text] [Related]
19. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
20. [Thyrotropin-secreting pituitary adenomas].
Caron P
Presse Med; 2009 Jan; 38(1):107-11. PubMed ID: 18980829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
